Nueva Guía VIH | Atención Primaria #AlDíaConLasGuías

Considerations in Primary Care for HIV Patients

Overview of the Guide

• The guide focuses on comprehensive care for HIV patients, extending beyond antiretroviral management to include initial paraclinical assessments and follow-up strategies.

• It emphasizes the importance of addressing non-infectious comorbidities, vaccination considerations, cancer care, and prevention of sexually transmitted infections (STIs).

Importance of Antiretroviral Therapy

• Effective antiretroviral therapy is crucial as HIV increasingly resembles a chronic illness; managing comorbidities and co-infections becomes essential.

• Mental health care is highlighted as vital, with an emphasis on stigma-free treatment environments.

Optimizing Patient Management

• Timely access to treatment is critical; rapid initiation of antiretroviral therapy should occur within 7 days post-diagnosis. This early intervention is key to ending the HIV epidemic.

• Certain conditions like meningitis due to tuberculosis or cryptococcosis may necessitate delaying treatment initiation. Emphasizing that effective management improves patient health and reduces transmission risk is important.

Stigma and Patient Identity

• The guide stresses avoiding stigma towards patients who have not achieved viral suppression, promoting the understanding that "undetectable equals untransmittable" (U=U).

• Healthcare centers should reflect diversity in staff and adopt inclusive language when referring to individuals living with HIV, using terms that affirm their identity. This includes proper use of pronouns and names chosen by patients themselves.

Multidisciplinary Approach

• A multidisciplinary team approach is necessary for comprehensive care; this includes medical professionals from various backgrounds working collaboratively rather than solely relying on physicians.

• Patients may require surgical interventions or dental procedures; decisions regarding these should involve multiple specialists rather than being based solely on viral load or CD4 counts. Additionally, patients living with HIV can be organ donors and recipients under appropriate circumstances.

Addressing Adherence Challenges

• Suboptimal adherence remains a significant barrier to effective treatment outcomes; it’s crucial not to penalize patients for missing doses but instead focus on solutions for improving adherence rates.

• Adherence extends beyond medication to include regular medical consultations and multidisciplinary support systems since non-adherent patients face higher mortality risks (over 50%).

Barriers to Treatment Access

• Various barriers hinder patient adherence: structural issues such as transportation difficulties, financial constraints related to healthcare costs, social insecurities affecting attendance at appointments, ethnic or migratory challenges impacting comfort during consultations are all significant factors that need addressing.

Innovative Care Models Post-Pandemic

• The pandemic has highlighted the need for alternative healthcare delivery models beyond traditional consultations; exploring innovative approaches could enhance patient engagement and adherence moving forward.

Innovative Approaches to HIV Patient Care

Unconventional Consultation Hours and Telemedicine

• The proposal includes unconventional consultation hours, such as nighttime appointments and street-level medical services, to enhance accessibility for patients.

• Telemedicine has emerged as a significant legacy of the COVID-19 pandemic, proving effective in patient care through both audio and video consultations.

• Audio-only consultations are also recognized as beneficial, particularly for vulnerable populations who may struggle with traditional healthcare access.

Initial Evaluation and Patient History

• The initial evaluation of HIV patients requires a comprehensive understanding of their medical history, focusing on their knowledge about their diagnosis and any fears or questions they may have.

• It is crucial to identify potential social barriers that could affect treatment adherence and to gather specific histories related to drug use practices among individuals who inject drugs.

Understanding Patient Background

• Gathering detailed information about the patient's past experiences with HIV treatment is essential, including previous CD4 counts and viral loads.

• Clinicians should inquire about any prior antiretroviral therapies received by the patient, reasons for discontinuation, and whether resistance testing has been conducted.

Comprehensive Medical Assessment

• A thorough medical assessment must include evaluations for opportunistic infections or cancers associated with HIV, alongside other chronic conditions like renal or hepatic diseases.

• Establishing trust with patients is vital; this allows open discussions regarding substance use without stigma.

System Review and Laboratory Tests

• The system review aims to uncover signs of undiagnosed conditions or opportunistic infections that may complicate the patient's health status.

• Initial laboratory tests should not delay treatment initiation; confirmation of an HIV diagnosis can be achieved through antigen-antibody tests within seven days.

Understanding Viral Load and HIV Management

Importance of Viral Load in Diagnosis

• The diagnosis of HIV cannot rely solely on viral load; it must be supported by antibody tests, especially for patients using cabotegravir as pre-exposure prophylaxis (PrEP).

• Cabotegravir has shown a significant rate of false positives in viral load tests, indicating that a positive result does not necessarily mean active infection.

Monitoring CD4 Counts and Treatment Decisions

• CD4 counts are crucial for assessing immunosuppression and the risk of opportunistic infections; however, CD8 counts and the CD4/CD8 ratio are less useful for decision-making.

• Achieving an undetectable viral load (U=U) is defined as having fewer than 200 copies/mL, which is an international guideline.

Genotyping and Resistance Testing

• Patients exposed to cabotegravir should undergo genotyping for integrase mutations due to potential false negatives in the absence of antiretroviral treatment.

• Prior to starting certain treatments like maraviroc, it's essential to assess the virus's tropism concerning CCR5.

Baseline Assessments Before Antiretroviral Therapy

• A comprehensive baseline assessment should include renal function tests, metabolic profiles, and hemogram before initiating antiretroviral therapy.

• Up to 30% of patients may experience renal function alterations upon starting treatment; thus monitoring is critical.

Risk Factors for Chronic Kidney Disease in HIV Patients

• Factors such as low CD4 counts (<200), high viral loads (>4000 copies), diabetes, hypertension, and co-infection with hepatitis C increase the risk of chronic kidney disease.

• Active screening for tuberculosis (TB) should occur if CD4 counts are below 200; annual follow-ups are recommended after initial testing.

Tuberculosis Screening Protocol

• For TB screening, a positive tuberculin skin test (PPD >5 mm) indicates potential infection. IGRA tests have lower cross-reactivity with BCG vaccination.

• If a patient with HIV has close contact with someone diagnosed with TB, latent infection treatment should commence regardless of test results.

Hepatitis Screening Guidelines

• Hepatitis B screening involves checking surface antigen levels and immunity status through antibody testing.

• For hepatitis C management post-infection resolution, monitoring should focus on viral load rather than antibodies due to possible reinfection risks.

Additional Considerations in Co-Infections

• In cases where there’s high suspicion of hepatitis C within six months post-exposure, viral load testing is advised despite previous negative antibody results.

• Special attention is needed for patients with severe immunosuppression (CD4 <200); they may present false negatives in hepatitis C antibody tests.

Routine Care Practices for HIV Patients

• Regular monitoring of viral load is essential once antiretroviral therapy begins to ensure patients achieve undetectable status.

Antiretroviral Treatment and Monitoring

Initial Control and Follow-Up

• Antiretroviral therapy requires an initial control within 4 to 8 weeks, followed by monitoring every 8 weeks until the patient achieves an undetectable viral load. After one year of being undetectable, follow-ups can shift to every 6 months.

Understanding Viral Blips

• A viral blip refers to a temporary increase in viral load in a patient who has previously achieved undetectability. This should be treated as an alert to investigate potential adherence issues or interactions with new medications.

Managing Persistent Viral Loads

• If a patient continues to show persistent viral loads after three months, it is classified as treatment failure. A genotypic study is required to identify any resistance and adjust antiviral management accordingly.

CD4 Monitoring and Mental Health Considerations

• CD4 counts should be monitored every 3 to 6 months for two years; thereafter, annual checks may suffice if levels are above 500. Mental health screening for depression, anxiety, substance use, and safe practices is essential during consultations.

Vaccination Guidelines for Pneumococcal Disease

• The pneumococcal vaccination schedule has evolved due to the introduction of new vaccines (e.g., pneumococcal 20/21). Recommendations vary based on prior vaccinations received and age, particularly emphasizing those over 65 or immunocompromised individuals.

Pneumococcal Vaccination Strategies

Vaccine Types and Recommendations

• Different pneumococcal vaccines (13, 15, 20, 21, and 25) have varying coverage for invasive infections. The choice of vaccine depends on previous vaccinations received and the patient's age.

Dosing Schedules Based on Previous Vaccinations

• For patients starting with pneumococcal vaccines like PCV13 or PPSV23, specific dosing schedules apply: e.g., if starting with PCV13 followed by PPSV23 at eight weeks intervals.

Completing the Vaccination Series

• Patients who begin their vaccination series with PPSV23 before age 65 will need additional doses later. If they start with PCV13 followed by PPSV23 at five-year intervals after age milestones are reached.

Visualizing Vaccination Protocols

• Graphical representations from CDC guidelines illustrate how vaccination protocols differ based on prior vaccine history and current recommendations for various age groups.

Final Notes on Vaccine Completion

• Patients who have completed their initial vaccination series may not require further doses unless specific conditions apply (e.g., receiving boosters after certain ages).

Vaccination Guidelines and Recommendations for Patients

Overview of Vaccination Doses

• Patients aged 19 to 50 years should receive a dose of either 20 or 21 to complete their vaccination schedule, especially if they have underlying conditions.

• If a patient has received vaccine 23, they can complete their schedule with doses of 20 or 21, or alternatively with dose 15.

• For hepatitis A vaccination, initial assessment is crucial; if no immunity is present, vaccination should be followed by a two-month evaluation for immune response.

Hepatitis B Vaccine Developments

• A new type of hepatitis B vaccine (BCG-PG) has been introduced that enhances immune response through an analog receptor (CpG), simplifying the vaccination process.

• The recommended scheme for immunosuppressed patients includes double doses while monitoring antibody levels to ensure effective immunity development.

Importance of Monitoring Immunity

• In cases where only core antibodies are detected without surface antibodies, revaccination may be necessary due to potential loss of previously developed immunity.

• It is advised that partners of patients with positive surface antigens receive vaccinations against various diseases including measles and varicella.

Additional Vaccination Considerations

• The recombinant shingles vaccine shows better responses in patients with CD4 counts above 200; there are no contraindications regarding COVID vaccines.

• RSV vaccination is recommended for individuals over 75 years old and those aged between 64 and 74 with comorbidities due to higher risks associated with severe infections.

Cancer Risks and Screening in HIV Patients

• General recommendations state that EMPO vaccinations are not indicated unless specific exposure risks exist; this includes recent sexual contact with diagnosed individuals.

• Two doses of the EMPO vaccine are required four weeks apart for at-risk populations identified through sexual health history.

Cancer Surveillance Strategies

• Increased cancer risk among HIV patients necessitates regular screenings similar to the general population, focusing on prostate, lung, colon, and breast cancers.

• Active surveillance strategies include mammograms every two years from ages 40 to 74 and anal cytology starting at age 45 for high-risk groups.

This structured overview provides insights into current vaccination guidelines and cancer screening recommendations tailored specifically for patients within certain demographics.

Health Screening and Management for Specific Populations

Importance of Regular Screenings

• Emphasizes the necessity of anoscopy for men who have sex with men, particularly if cervical cytology results are abnormal.

• Highlights the need for annual rectal exams regardless of availability due to increased cancer risk in older populations, especially among African American men.

Considerations for Transgender Patients

• Stresses that patients with neovagina should undergo regular rectal and vaginal examinations to assess prostate health.

• Notes higher mortality rates from cancer in transgender individuals due to diagnostic challenges and treatment access issues.

STI Screening Protocols

• Discusses the importance of creating a stigma-free environment for STI discussions, encouraging open communication about sexual health.

• Recommends active screening for gonorrhea and chlamydia using nucleic acid tests based on sexual contact types (oral, anal, urethral).

Follow-Up Procedures After Positive Results

• Advises follow-up testing every three months after positive results for syphilis, gonorrhea, or trichomonas due to high reinfection rates.

• Suggests conducting sensitivity tests if symptoms persist post-treatment or if there is an increase in titers without evidence of reinfection.

Special Considerations During Pregnancy

• Recommends screening for syphilis, chlamydia, and gonorrhea during initial consultations and at 28 weeks gestation; only syphilis and trichomonas at delivery.

• Outlines treatment protocols: early-stage syphilis treated with benzathine penicillin or doxycycline; neurosyphilis requires crystalline penicillin.

Addressing Emerging Infections

• Reports on rising global resistance patterns in mycoplasma infections; emphasizes careful consideration before treating asymptomatic cases.

• Discusses monitoring symptoms following exposure to certain infections within three weeks; highlights vaccination opportunities shortly after exposure.

This structured summary provides a comprehensive overview of key health management strategies tailored specifically towards vulnerable populations while emphasizing the importance of regular screenings and proactive healthcare measures.

Doxycycline Use in STI Prevention

Overview of Doxycycline Studies

• The American stance on doxycycline for STI prevention is based on four key studies, including the Hiper Gay study and others focusing on its efficacy.

• Doxycycline (200 mg) is recommended ideally within 24 hours and up to 72 hours post sexual contact to prevent STIs such as syphilis, chlamydia, and gonorrhea.

Efficacy in Different Populations

• Research primarily involves men who have sex with men (MSM), transgender women, while studies involving women showed inadequate results in STI prevention.

• Recommendations suggest offering doxycycline to high-risk individuals, including bisexual men and MSM who had syphilis or chlamydia in the past year.

Considerations for Other Demographics

• Current data lacks clarity regarding doxycycline's effectiveness for heterosexual men, transgender individuals, and non-binary genders; individualized discussions are necessary.

Comorbidities Associated with HIV

Aging Population with HIV

• Approximately 50% of people living with HIV are over 50 years old, facing comorbidities like cardiovascular diseases and diabetes.

• Individuals with HIV show increased risks of weight gain, bone mineral loss, chronic illness, hypogonadism, frailty, and neurocognitive disorders.

Lipid Alterations Due to Antiretroviral Therapy

• Antiretroviral therapy impacts lipid levels; protease inhibitors can raise LDL/HDL levels without returning them to pre-treatment levels.

• The REPR study indicated that rosuvastatin reduced carotid intima thickness and improved renal function among patients with low viral loads.

Statin Recommendations for Cardiovascular Health

Statin Use Guidelines

• A recommendation exists for statin use in all individuals aged 40 to 75 years living with HIV; those under 40 should have personalized decisions made.

Drug Interactions and Management

• Protease inhibitors can inhibit metabolism of certain statins (simvastatin/lovastatin); atorvastatin/rosuvastatin should be initiated at lower doses due to higher concentration risks.

Diabetes Management in Patients with HIV

Monitoring Blood Sugar Levels

• Various methods can assess blood sugar before starting antiretroviral treatment; however, hemoglobin A1c may not accurately diagnose diabetes in those with HIV.

Impact of Medications on Diabetes Diagnosis

• Certain medications affect glucose readings; diabetic patients can continue using these medications for monitoring as per guidelines while considering lifestyle changes.

Weight Gain Concerns Among Diverse Populations

Observations on Weight Changes

• Weight gain has been noted particularly among non-white populations following current treatment regimens.

Discussion on Tenofovir and Weight Management in HIV Treatment

Impact of Antiretroviral Medications on Weight

• The association between tenofovir, integrase inhibitors, and weight changes is debated; it's unclear if these medications cause weight gain or if comparators like tenofovir lead to weight loss.

• Studies indicate that pre-exposure prophylaxis (PrEP) with tenofovir can result in weight loss, but this may not be beneficial due to potential mitochondrial toxicity associated with the drug.

Importance of Monitoring Health Parameters

• Emphasis on maintaining physical activity regardless of weight changes; mere weight increase should not prompt a change in antiretroviral management.

• Liver health is crucial; fatty liver disease can elevate transaminases, necessitating monitoring for patients with lower body mass indices.

Evaluating Liver Disease and Bone Health

• Patients with hepatic steatosis require evaluation through imaging techniques like ultrasound or elastography to assess fibrosis levels.

• Attention must be given to secondary causes of osteoporosis such as vitamin D deficiency and lifestyle factors; antiretroviral therapy based on tenofovir can exacerbate bone density reduction.

Recommendations for Osteoporosis Screening

• Routine screening for osteoporosis via bone densitometry is advised for individuals over 50 years old living with HIV.

• Vitamin D deficiency should not be routinely screened unless symptomatic; lifestyle modifications including exercise and calcium intake are essential.

Considerations for Reproductive Health in HIV Patients

• Inquiry into gestational desires is important for reproductive planning; contraceptive options should be discussed while considering interactions with antiretroviral therapy.

• Preconception counseling includes folic acid supplementation and discussing PrEP use among serodiscordant couples to minimize transmission risk.

Managing Pregnancy and Lactation in HIV-positive Individuals

• Continuous antiretroviral treatment before pregnancy significantly reduces transmission risks during childbirth.

• Cesarean delivery is recommended if viral load status is unknown or high-risk exposure has occurred. Breastfeeding decisions should consider local feeding alternatives.

Addressing Needs of Transgender Individuals in Healthcare

• Ensuring access to gender affirmation therapies without stigma is vital; healthcare providers must respect gender identity in clinical documentation.

• Awareness of drug interactions between gender affirmation therapies (estradiol/testosterone) and antiretrovirals is critical for safe treatment plans.